Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis: an Exploratory Study
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test
研究概览
简要总结
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of anxiety symptoms and an addictive profile. However, no study to date has precisely investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH patients.
This study should allow:
- to assess the prevalence of psychiatric disorders co-morbid in PLCH patients
- a targeted and more effective management of patients
- a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of 18 years of age or older with PLCH diagnosed at adulthood
- •Patients affiliated to the French Health Care System
- •Informed patients
排除标准
- •Patient unable to understand the interview (language barrier)
- •Patient under guardianship or curatorship
- •Patient under AME (French medical help for foreigners)
结局指标
主要结局
Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test
时间窗: at inclusion
The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder
次要结局
- Proportion of patients with active tobacco consumption with or without comorbid psychiatric disorder(at inclusion)
- Proportion of patients with persistent tobacco consumption despite nicotine replacement treatment(at inclusion)
- Proportion of patients with at least one comorbid addictive disorder among: tobacco, alcohol, cannabis, benzodiazepines, cocaine, opiates(at inclusion)
- Number of co-morbid psychiatric disorders(at inclusion)
- Factors associated with psychiatric disorders as assessed by Mini International Neuropsychiatric Interview (MINI) test(at inclusion)
- Number of previous tobacco weaning episodes and co-morbid psychiatric disorders(at inclusion)